How Much Tesamorelin Should You Take? A Practical Dosing Guide

Tesamorelin at a glance:

• Drug class: GHRH analog
• Manufacturer: Theratechnologies
• FDA approved: 2010
• Route: subcutaneous injection
• Typical frequency: once daily
• Half-life: approximately 26-38 minutes
• Cash price (US): $3,000-$4,000/month without insurance

Here's the core rule for Tesamorelin dosing: titrate slowly, hold each step long enough, and don't try to outpace your body. Approved dose is 2 mg subcutaneously once daily.

Standard Dosing Schedule for Tesamorelin

Approved dose is 2 mg subcutaneously once daily.

The typical schedule for Tesamorelin is once daily via subcutaneous injection. Half-life of approximately 26-38 minutes explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For this class of compound, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms .

A typical titration plan for Tesamorelin holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of Tesamorelin is missed: for daily schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (approximately 26-38 minutes) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in Tesamorelin side effects and the cost angle of dose escalation in Tesamorelin cost.

What the Trials Used

Published trial data for Tesamorelin comes primarily from: Stanley et al. 2010, NEJM — visceral adipose tissue reduction in HIV-lipodystrophy.

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For Tesamorelin: the standard contraindications for this drug class apply.

Bottom Line

Tesamorelin dosing isn't intuitive but it isn't complicated either. Follow the schedule, talk to your prescriber when something feels off, and don't make changes on your own.

Frequently Asked Questions

Related Reading

• Is Tesamorelin Right for You? An Evidence-Based Breakdown
• Is Tesamorelin Safe? An Honest Look at the Side-Effect Profile
• Tesamorelin Results: What the Real Numbers Show in 2026
• Why Tesamorelin Costs So Much (and 5 Ways to Pay Less)
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.
• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.
• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.

This page is informational only and is not medical advice. We do not provide guidance for self-administration of compounds that are not FDA-approved.